IFNB1 and myeloid sarcoma: Since the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe approved the first therapeutic agent, the interferon-beta (IFNβ) [1], more than a dozen of drugs for the treatment of MS have been developed and several new potential molecules will become available soon.